Abbott Laboratories
conquer expectations for its 3rd quarter and raised its earnings outlook for the whole yr, but pointed out that quarterly product sales took a strike from Covid-19 screening declines and shortages of infant system.
For the 3rd quarter that finished Sept. 30, Abbott (ticker: ABT) noted adjusted earnings of $1.15 a share on sales of $10.4 billion. Analysts polled by FactSet were being anticipating adjusted earnings of 94 cents a share on product sales of $9.6 billion. In the exact same period final 12 months, Abbott posted earnings of $1.40 a share on income of $10.9 billion.
Abbott Laboratories
conquer expectations for its 3rd quarter and raised its earnings outlook for the whole yr, but pointed out that quarterly product sales took a strike from Covid-19 screening declines and shortages of infant system.
For the 3rd quarter that finished Sept. 30, Abbott (ticker: ABT) noted adjusted earnings of $1.15 a share on sales of $10.4 billion. Analysts polled by FactSet were being anticipating adjusted earnings of 94 cents a share on product sales of $9.6 billion. In the exact same period final 12 months, Abbott posted earnings of $1.40 a share on income of $10.9 billion.
